Osiris Therapeutics rises on Medicare decision

Shares of Osiris Therapeutics Inc. rose Wednesday after the stem cell product developer said Medicare is assigning reimbursement codes to its Grafix skin therapy.

Read more:

Osiris Therapeutics rises on Medicare decision

Related Posts

Comments are closed.